Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Viking Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.vikingtherapeuti...
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: Brian Lian, PhD, MBA
Number Of Employees: 36
Enterprise Value: $3,486,155,880
PE Ratio: -24.01
Exchange/Ticker 1: NASDAQ:VKTX
Exchange/Ticker 2: N/A
Latest Market Cap: $2,718,646,528
BioCentury | Jan 25, 2025
Product Development
Amylin is back with Novo’s positive amycretin data
Injectable amycretin shows 24% placebo-adjusted weight loss, giving it the lead in efficacy — at least for now
BioCentury | Dec 20, 2024
Product Development
Novo’s market cap slims down on CagriSema obesity data
Placebo-adjusted weight loss falls short of 25%+ expectations, doesn’t differentiate from Lilly’s Zepbound
BioCentury | Nov 15, 2024
Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
BioCentury | Nov 5, 2024
Deals
Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist
Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers
BioCentury | Nov 5, 2024
Product Development
Viking continues push for VK2735 as best in class in obesity
Dual GIP/GLP-1 agonist shows highly competitive efficacy, safety, dosing flexibility; although oral dose could limit commercial supply
BioCentury | Sep 20, 2024
Product Development
Novo’s Phase II miss in obesity oral amps up pressure on BD
Ph II data from CB1 blocker monlunabant show poor weight loss at 16 weeks, plus neuropsychiatric adverse events
BioCentury | Sep 11, 2024
Product Development
Amycretin data highlight supply challenges for oral peptides in obesity
Although efficacy was strong, high dose likely makes oral amycretin commercially unviable
BioCentury | Sep 10, 2024
Product Development
More contenders enter oral obesity race
But efficacy for oral GLP-1 agonist TERN-601, ecnoglutide still falls short of Roche, Novo
BioCentury | Jul 31, 2024
Product Development
Clinical Report: BioNTech claims mRNA cancer vaccine success
Plus data from NewAmsterdam, Pfizer, Calliditas, Ventyx and Viking
BioCentury | Jul 9, 2024
Finance
2Q24 Wrap: Trickle down recovery?
Biopharmas above $5B in market cap are up, but everyone else languishes
Items per page:
1 - 10 of 80